<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908579</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 87/ 2021</org_study_id>
    <nct_id>NCT04908579</nct_id>
  </id_info>
  <brief_title>Efficacy of Preventive Ketamine on Postoperative Pain</brief_title>
  <official_title>Efficacy of Preventive Ketamine on Postoperative Pain: A Randomized, Double-blind Trial of Patients Undergoing Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Although bariatric surgery is mainly performed laparoscopically, analgesic optimization&#xD;
           is still essential to reduce complications and to improve the patients' comfort. In&#xD;
           laparoscopic sleeve gastrectomy, the intraoperative peritoneal instillation of&#xD;
           bupivacaine hydrochloride (30 ml, 0.25%) was known to be safe and effective in reducing&#xD;
           postoperative pain, nausea, and vomiting.&#xD;
&#xD;
        -  Furthermore, usage of ketamine both as a pre and post-operative pain management is well&#xD;
           established. Ketamine can be used solely or in combination with other co-adjuvant drugs,&#xD;
           increasing their efficacy. Many therapeutic properties of ketamine have been attributed&#xD;
           to its antagonism mechanism to N-Methyl-D-aspartate receptors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first given rescue analgesia(minutes)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Time to first given rescue analgesia(minutes)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>- GROUP (I): 30 patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>- GROUP (II): 30 patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>- GROUP (III) (Control): 30 patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine(intraperitoneally) and ketamine (intraperitoneally)</intervention_name>
    <description>40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration&#xD;
10 ml normal saline 0.9% will be given intravenous.</description>
    <arm_group_label>- GROUP (I): 30 patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine(intraperitoneally) and ketamine (intravenously)</intervention_name>
    <description>40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration&#xD;
10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.</description>
    <arm_group_label>- GROUP (II): 30 patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine(intraperitoneally)</intervention_name>
    <description>40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration&#xD;
10 ml normal saline 0.9% will be given intravenous.</description>
    <arm_group_label>- GROUP (III) (Control): 30 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Body mass index &gt; 35 and &lt; 60 kg/m2&#xD;
&#xD;
          -  Either medically free or with well controlled hypertension and/or diabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patient's refusal to participate in the study&#xD;
&#xD;
          -  BMI &gt; 60 kg/m2.&#xD;
&#xD;
          -  Age less than 21 years.&#xD;
&#xD;
          -  Patients with severe systemic disease which is not life-threatening.&#xD;
&#xD;
          -  Patients on antipsychotics, antidepressants and/or corticosteroids.&#xD;
&#xD;
          -  Patients with history of obstructive sleep apnea.&#xD;
&#xD;
          -  Allergic reaction to any of the study medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ibrahim Mamdouh Esmat</last_name>
    <phone>01001241928</phone>
    <email>ibrahim_mamdouh@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain-Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Mamdouh Esmat</last_name>
      <phone>01001241928</phone>
      <email>ibrahim_mamdouh@med.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr.Ibrahim Mamdouh Esmat</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

